B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Order to Cash Analyst

Full-TimeUpdated on 10/15/2026
No salary listed
Mid
Bachelor's
Mexico City, CDMX, Mexico
Hybrid
AccountingAccounts Payable/Receivable

About the job

Requirements
  • A bachelor's degree in Finance, Accounting, Business Administration, Economics, or a related field is required.
  • A minimum of four years of relevant experience is required.
  • Proven experience in an Order to Cash role within the pharmaceutical industry, with a solid understanding of billing, accounts receivable, collections, and cash application processes.
  • Experience with SAP or similar enterprise resource planning systems; SAP experience is highly preferred.
  • Knowledge of Mexican invoicing and local business requirements is highly desirable.
  • Strong analytical skills and attention to detail, with the ability to identify and resolve discrepancies in a timely manner.
  • Strong organizational skills and the ability to manage multiple priorities and deadlines in a dynamic environment.
  • Ability to work effectively across Finance, Accounting, Commercial, Supply Chain, Customer Service, and Tax functions.
  • Strong communication and interpersonal skills, with the ability to interact effectively with internal stakeholders and external customers or service providers.
  • English proficiency sufficient to communicate effectively in a regional and global corporate environment.
  • Ability to travel within Mexico.
  • SAP experience, advanced Excel, and PowerPoint skills.
Responsibilities
  • Support end-to-end Order to Cash processes for the company’s operations in Mexico, ensuring accurate and timely execution of customer orders, invoicing, accounts receivable, collections, cash application, and related financial activities.
  • Work closely with Commercial, Supply Chain, Customer Service, and external service providers to support efficient O2C operations and compliance with company policies, internal controls, and local regulatory requirements.
  • Prepare and issue customer invoices and related commercial documentation; monitor customer accounts and outstanding receivables; support collection activities; resolve billing and payment discrepancies; and reconcile and apply customer payments.
  • Support credit-related processes and provide visibility into overdue balances, collection performance, and potential financial risks.
  • Support transactions involving private and institutional customers, distributors, and other commercial partners, coordinating stakeholders in the revenue and collection cycle.
  • Contribute to continuous improvement and standardization of O2C processes; support implementation and effective use of SAP and other financial systems; and maintain documentation and controls for operational efficiency, financial accuracy, and audit readiness.
  • Prepare, review, and issue customer invoices, credit notes, debit notes, and related commercial documentation, ensuring accuracy and compliance with local requirements and company policies.
  • Execute and support daily O2C activities, ensuring transactions are processed accurately and within established timelines.
  • Monitor Accounts Receivable balances and aging, follow up on outstanding and overdue invoices, and support collection activities.
  • Perform cash application and customer account reconciliations, ensuring payments are properly identified and allocated.
  • Investigate and resolve billing, payment, collection, and account discrepancies with customers and relevant internal teams.
  • Maintain accurate and complete customer master data and O2C documentation in SAP and other applicable systems.
  • Support credit management activities, including monitoring credit limits, payment terms, and customer exposure.
  • Prepare periodic Accounts Receivable and O2C reports, including aging, overdue balances, collections, cash application status, and other relevant key performance indicators.
  • Coordinate with Commercial, Finance, Accounting, Supply Chain, Customer Service, Tax, and external service providers to support an efficient end-to-end O2C process.
  • Ensure compliance with internal controls, financial policies, local tax and invoicing requirements, and maintain documentation for internal and external audits.
  • Support month-end closing activities related to Accounts Receivable, revenue, billing, collections, and customer account reconciliations.
  • Identify opportunities for process improvement, standardization, and automation across O2C activities and support their implementation.
Desired Qualifications
  • Pharmaceutical or biotechnology industry experience.
  • SAP experience is highly preferred.
  • Knowledge of Mexican invoicing and local business requirements is highly desirable.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.